Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1876
https://www.valueinhealthjournal.com/article/S1098-3015(16)33242-9/fulltext
Title :
Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33242-9&doi=10.1016/j.jval.2016.09.1876
First page :
A673
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1773